View ValuationBoundless Bio 향후 성장Future 기준 점검 0/6Boundless Bio 의 수익이 6.9%로 연간 감소할 전망입니다. 주당 순이익은 성장 연간 15.6%만큼 감소할 것으로 예상됩니다.핵심 정보-6.9%이익 성장률15.60%EPS 성장률Biotechs 이익 성장25.2%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트11 May 2026최근 향후 성장 업데이트Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.모든 업데이트 보기Recent updates공시 • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.공시 • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.분석 기사 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.분석 기사 • Oct 17Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.공시 • Jun 30+ 16 more updatesBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth IndexBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth Index공시 • May 26+ 1 more updateBoundless Bio, Inc. Announces Workforce Reduction of Approximately One-Third of the Company’s WorkforceOn May 23, 2025, Boundless Bio, Inc. announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits. The Company estimates that the workforce reduction will be substantially completed in the second quarter of 2025 and that the majority of the related charges will be recognized in the Company’s second quarter financial results of operations. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the implementation of the workforce reduction.공시 • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025.New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$94m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$32.3m market cap).공시 • Feb 03Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerBoundless Bio, Inc. announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. Dr. Doebele was the co-founder of Rain Oncology, Inc., (acquired by Pathos AI), a precision oncology company, where he served as Chief Scientific and Medical Officer, directing the research and development of innovative therapies targeting oncogenic drivers in tumor-agnostic, biomarker-driven trials. Specifically, he led the clinical development plans for milademetan, a small molecule MDM2 inhibitor, Phase 2 planning for tarloxotinib, a hypoxia-activated pan-HER kinase inhibitor, and the development of a preclinical program focused on inducing synthetic lethality by inhibiting RAD52. Dr. Doebele previously led the research and clinical trials at the University of Colorado that launched the TRK inhibitor field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib). He also served as the director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and co-founded and co-directed the University of Colorado Molecular Tumor Board. Dr. Doebele received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine and an A.B. in Molecular Biology from Princeton University.분석 기사 • Jan 13Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • Dec 13+ 1 more updateBoundless Bio, Inc. Changes to Management TeamBoundless Bio, Inc. announced that Klaus Wagner, M.D., Ph.D., Chief Medical Officer (CMO), and Neil Abdollahian, Chief Business Officer (CBO), will depart the company at the end of December and in early January 2025, respectively. James L. Freddo, M.D., current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as Interim CMO while the company conducts a search for a permanent hire. Dr. Freddo’s extensive background includes serving as CMO and later as a member of the board of directors at Ignyta, Inc., CMO and Senior Vice President, Development at Anadys Pharmaceuticals, and Vice President, Clinical Development, Oncology at Pfizer. The company does not intend to appoint a new CBO at this time.공시 • Oct 14Boundless Bio Announces Departure of Jami Rubin as Chief Financial OfficerBoundless Bio announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer.분석 기사 • Sep 27Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...공시 • Aug 13Boundless Bio Provides Business Updates Focused on Key Value DriversBoundless Bio, Inc. provided business updates for the company's top strategic priorities. In alignment with its strategic priorities, Boundless Bio has narrowed its discovery research work and, as a result, modestly reduced its workforce. BBI-355, a novel, oral, potent, selective CHK1 inhibitor targeting replication stress for cancer patients with driver oncogene amplifications. The company presented preclinical and clinical pharmacodynamic data on BBI-355 at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. Enrollment is progressing in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a single agent and in combination with targeted therapies in patients with locally advanced or metastatic solid tumors with oncogene amplifications. BBI-825, a novel, oral, powerful RNR inhibitor targeting ecDNA assembly and repair for cancer patients with resistance oncogene amplifications. In April 2024, the company announced the first patient had been dosed with BBI-825 in the Phase 1/2 STARMAP clinical trial. ECTA was previously determined by the FDA to be a non-significant risk device for use as a clinical trial assay (CTA) in the BBI-355 POTENTIATE trial. About BBI-355: BBI-355, is a novel, oral, selective small molecule inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTentIATE clinical trial (NCT05827614) in cancer patients with oncogene amplifications; BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Actual results may difference from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: the potential for its programs and prospects to be negatively impacted by developments relating to competitors, including the results of studies or regulatory decisions relating to competitors; regulatory developments in the United States and foreign countries; efforts to streamline operations may not produce the efficiencies expected; may use capital resources later than expect; and other risks described in its business.공시 • Apr 11Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsBoundless Bio announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells. BBI-825, the Company's second ecDNA-directed therapy (ecDTx) to enter clinical trials, is a novel, selective, oral small molecule inhibitor of ribonucleotide reductase (RNR), a rate-limiting enzyme responsible for the de novo synthesis of deoxyribonucleotides, the building blocks of DNA. Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.공시 • Mar 29Boundless Bio, Inc. has completed an IPO in the amount of $100 million.Boundless Bio, Inc. has completed an IPO in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Sponsor Backed OfferingBoard Change • Mar 28High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Independent Chairman Jonathan Lim is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.이익 및 매출 성장 예측NasdaqGS:BOLD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-71N/AN/A112/31/2027N/A-64N/AN/A212/31/2026N/A-55N/AN/A23/31/2026N/A-56-48-47N/A12/31/2025N/A-58-47-47N/A9/30/2025N/A-62-53-52N/A6/30/2025N/A-64-56-55N/A3/31/2025N/A-66-62-60N/A12/31/2024N/A-65-63-61N/A9/30/2024N/A-61-59-57N/A6/30/2024N/A-58-58-56N/A3/31/2024N/A-53-51-51N/A12/31/2023N/A-49-47-47N/A9/30/2023N/A-49-46-45N/A6/30/2023N/A-49-44-44N/A3/31/2023N/A-47-43-42N/A12/31/2022N/A-46-41-40N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BOLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: BOLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: BOLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: BOLD 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: BOLD 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BOLD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 13:08종가2026/05/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Boundless Bio, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hiroshi ShibutaniGoldman SachsRichard J. LawGoldman SachsMichael SchmidtGuggenheim Securities, LLC1명의 분석가 더 보기
Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.
Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.
공시 • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.
공시 • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.
New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).
Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.
분석 기사 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.
분석 기사 • Oct 17Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.
공시 • Jun 30+ 16 more updatesBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth IndexBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth Index
공시 • May 26+ 1 more updateBoundless Bio, Inc. Announces Workforce Reduction of Approximately One-Third of the Company’s WorkforceOn May 23, 2025, Boundless Bio, Inc. announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits. The Company estimates that the workforce reduction will be substantially completed in the second quarter of 2025 and that the majority of the related charges will be recognized in the Company’s second quarter financial results of operations. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the implementation of the workforce reduction.
공시 • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025.
New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$94m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$32.3m market cap).
공시 • Feb 03Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerBoundless Bio, Inc. announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. Dr. Doebele was the co-founder of Rain Oncology, Inc., (acquired by Pathos AI), a precision oncology company, where he served as Chief Scientific and Medical Officer, directing the research and development of innovative therapies targeting oncogenic drivers in tumor-agnostic, biomarker-driven trials. Specifically, he led the clinical development plans for milademetan, a small molecule MDM2 inhibitor, Phase 2 planning for tarloxotinib, a hypoxia-activated pan-HER kinase inhibitor, and the development of a preclinical program focused on inducing synthetic lethality by inhibiting RAD52. Dr. Doebele previously led the research and clinical trials at the University of Colorado that launched the TRK inhibitor field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib). He also served as the director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and co-founded and co-directed the University of Colorado Molecular Tumor Board. Dr. Doebele received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine and an A.B. in Molecular Biology from Princeton University.
분석 기사 • Jan 13Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • Dec 13+ 1 more updateBoundless Bio, Inc. Changes to Management TeamBoundless Bio, Inc. announced that Klaus Wagner, M.D., Ph.D., Chief Medical Officer (CMO), and Neil Abdollahian, Chief Business Officer (CBO), will depart the company at the end of December and in early January 2025, respectively. James L. Freddo, M.D., current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as Interim CMO while the company conducts a search for a permanent hire. Dr. Freddo’s extensive background includes serving as CMO and later as a member of the board of directors at Ignyta, Inc., CMO and Senior Vice President, Development at Anadys Pharmaceuticals, and Vice President, Clinical Development, Oncology at Pfizer. The company does not intend to appoint a new CBO at this time.
공시 • Oct 14Boundless Bio Announces Departure of Jami Rubin as Chief Financial OfficerBoundless Bio announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer.
분석 기사 • Sep 27Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
공시 • Aug 13Boundless Bio Provides Business Updates Focused on Key Value DriversBoundless Bio, Inc. provided business updates for the company's top strategic priorities. In alignment with its strategic priorities, Boundless Bio has narrowed its discovery research work and, as a result, modestly reduced its workforce. BBI-355, a novel, oral, potent, selective CHK1 inhibitor targeting replication stress for cancer patients with driver oncogene amplifications. The company presented preclinical and clinical pharmacodynamic data on BBI-355 at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. Enrollment is progressing in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a single agent and in combination with targeted therapies in patients with locally advanced or metastatic solid tumors with oncogene amplifications. BBI-825, a novel, oral, powerful RNR inhibitor targeting ecDNA assembly and repair for cancer patients with resistance oncogene amplifications. In April 2024, the company announced the first patient had been dosed with BBI-825 in the Phase 1/2 STARMAP clinical trial. ECTA was previously determined by the FDA to be a non-significant risk device for use as a clinical trial assay (CTA) in the BBI-355 POTENTIATE trial. About BBI-355: BBI-355, is a novel, oral, selective small molecule inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTentIATE clinical trial (NCT05827614) in cancer patients with oncogene amplifications; BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Actual results may difference from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: the potential for its programs and prospects to be negatively impacted by developments relating to competitors, including the results of studies or regulatory decisions relating to competitors; regulatory developments in the United States and foreign countries; efforts to streamline operations may not produce the efficiencies expected; may use capital resources later than expect; and other risks described in its business.
공시 • Apr 11Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsBoundless Bio announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells. BBI-825, the Company's second ecDNA-directed therapy (ecDTx) to enter clinical trials, is a novel, selective, oral small molecule inhibitor of ribonucleotide reductase (RNR), a rate-limiting enzyme responsible for the de novo synthesis of deoxyribonucleotides, the building blocks of DNA. Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.
공시 • Mar 29Boundless Bio, Inc. has completed an IPO in the amount of $100 million.Boundless Bio, Inc. has completed an IPO in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Sponsor Backed Offering
Board Change • Mar 28High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Independent Chairman Jonathan Lim is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.